Rhythm Q4 2024 IMCIVREE revenue $41.8M; cash runway extended to 2027

RHYTHM PHARMACEUTICALS, INC.

2024-FY EPS reported -$4.34 revenue$130,126,000

Q4 2024 IMCIVREE net revenue $41.8M (+26% sequential, +73% YoY); FY2024 total $130.1M.
Net loss Q4 2024 ($44.6M) or ($0.72)/share vs ($41.6M) in Q4 2023; FY loss ($264.6M).
Raised ~$75M gross proceeds from ATM (1.3M shares at ~$56.30); cash $320.6M at Dec 31, 2024.
FDA and UK MHRA expanded IMCIVREE label to children as young as 2 years old.
Phase 3 acquired hypothalamic obesity trial topline data expected Q2 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.